AAPG · ASCENTAGE PHARMA GROUP INTERNATIONAL

📣 What AAPG Says Is Next

• In 2026 · “Expected Progress of Olverembatinib In 2026, we will continue to advance enrollment in the POLARIS-1, POLARIS-2, and POLARIS-3 trials. 11 Key Products and Pipeline Candidates Lisaftoclax (APG-2575) Lisaftoclax is a novel, oral Bcl-2 inhibitor developed to treat a variety of hematologic malignancies and solid tumors by selectively blocking Bcl-2 to restore the normal apoptotic process in cancer cells.”
  Company press release, Mar 26, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Dec 2026 · Phase 2 · Recruiting · Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
  Registry primary completion date, not a results date
• Dec 2026 · Phase 3 · Recruiting · Global Trial in APG2575 for Patients With CLL/SLL
  Registry primary completion date, not a results date
• Mar 2027 · Phase 3 · Recruiting · A Study of Olverembatinib in SDH-deficient GIST.
  Registry primary completion date, not a results date
• May 2027 · Phase 1 · Recruiting · APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurr
  Registry primary completion date, not a results date
• Jun 2027 · Phase 1/2 · Recruiting · APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or
  Registry primary completion date, not a results date
• Jun 2027 · Phase 3 · Recruiting · Study of Olverembatinib (HQP1351) in Patients With CML-CP
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not AAPG's own candidates): Acalabrutinib, Rituximab, Chlorambucil, Bosutinib, Gemcitabine Hydrochloride, Toripalimab, Ibrutinib, Imatinib, Palbociclib, Pembrolizumab, Lenalidomide, Brentuximab Vedotin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AAPG holds $1.9B in cash and short-term investments and burns about $330.8M/quarter from operations, an estimated runway of 17.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

• Cash runway 17 months +18
• ATM program on file since Jul 2026 +15
• Shelf registration (F-3ASR, Jul 2026) +10

Recent financing filings on SEC EDGAR:

• Jul 20, 2026 · Shelf registration with ATM program, up to $200M · F-3ASR
• Jan 24, 2025 · Underwritten offering · 424B4
• Dec 27, 2024 · S-1 registration · F-1

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AAPG files for a raise →

👥 Who Owns AAPG

Share count 373,322,192 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.